Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Topic: Hepatitis C Virus and Hepatocellular Carcinoma - Recent Advances

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 1 Jul 2021

Guest Editor(s)

  • James Fung, MD
    Consultant and Honorary Associate Professor in the Division of Gastroenterology and Hepatology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.

    Website | E-mail

  • Lung-Yi Mak
    Clinical Assistant Professor, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China.

    Website | E-mail

Special Issue Introduction

Chronic hepatitis C virus (HCV) infection is an important cause of hepatocellular carcinoma (HCC). In the past, pegylated interferon with ribavarin was the only treatment available, which conferred limited efficacy and is contraindicated in patients with decompensated cirrhosis and other medical conditions such as autoimmune illnesses, psychiatric diseases and heart failure. The approval of direct-acting antivirals (DAAs) in recent years has led to dramatic increase in the cure rate of chronic HCV infection. Consequently, the complications arising from HCV, including HCC and decompensated cirrhosis, are expected to be declining. In this special issue, the following topics will be discussed:

• The changing epidemiology of HCV-related HCC
• Pathogenesis of HCV-related HCC
• Prediction of risk of HCC in HCV-infected patients
• Prevention and early detection of HCC in chronic HCV infection
• Efficacy and safety of DAAs for the treatment of HCV-related HCC
• Treatment strategy for HCV-related cirrhosis and HCC
• Risk of HCC after antiviral treatment for HCV – fact or fiction?
• Role of DAAs in HCV-related HCC in patients undergoing surgical resection
• Management of HCV in HCC patients undergoing liver transplantation


1. Alshymaa Hassnine Gasteroentrology and Tropical Diseases, Minia University Faculty of Medicine, El Minia, Egypt.
2. Muhammad Hafeez PEMH, Med Unit 3, Rawalpindi, Pakistan.
3. En-Qiang Chen Sichuan University, West China Hosp, Ctr Infect Dis, Chengdu, Sichuan, China.
4. Hend Ibrahim Shousha Department of Endemic Medicine and Hepatogastroenterology, Faculty of Medicine, Cairo University, Egypt.
5. Hany Khalil Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Sadat City, Egypt.
6. Maha Elsabaawy Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt.
The list is arranged in no particular order and being updated.

Submission Deadline

1 Jul 2021

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 1 Jul 2021
Contacts: Victoria Lee, Assistant Editor,

Published Articles

This special issue is now open for submission.
© 2016-2021 OAE Publishing Inc., except certain content provided by third parties